Levetiracetam Sandoz (Levetiracetam)

Levetiracetam is an anticonvulsant indicated for several seizure types.

• Partial‑onset seizures: provides adjunctive seizure control when added to existing therapy.
• Myoclonic seizures: reduces the frequency of myoclonic jerks as part of combination treatment.
• Primary generalized tonic‑clonic seizures: helps achieve better seizure control in patients with this seizure type.

• Levetiracetam binds selectively to the synaptic vesicle protein SV2A, modulating neurotransmitter release. This interaction stabilises neuronal membranes and reduces excessive neuronal firing, thereby decreasing seizure activity without significant interaction with traditional ion‑channel targets.

Levetiracetam may cause a range of adverse reactions.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Fatigue: increased tiredness or lack of energy.
• Somnolence: sleepiness or drowsiness.
• Headache: mild to moderate head pain.
• Irritability: mood changes or agitation.
• Nausea: upset stomach or feeling of queasiness.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
• Suicidal ideation: thoughts of self‑harm or depression.
• Severe skin reactions: including toxic epidermal necrolysis.
• Blood dyscrasias: abnormal blood counts.
• Respiratory depression: difficulty breathing, especially with CNS depressants.
• Anaphylaxis: acute allergic reaction with rash, swelling, or airway compromise.

When using Levetiracetam, consider the following safety measures.

• Renal impairment: adjust dosing in patients with reduced kidney function.
• Abrupt discontinuation: taper gradually to avoid increased seizure frequency.
• Concomitant CNS depressants: monitor for enhanced sedation or respiratory effects.
• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Lactation: assess risk versus benefit before prescribing to nursing mothers.
• Store at ambient temperature: keep in the original container, protect from light and moisture.

Levetiracetam has a relatively low interaction profile, but certain combinations require attention.

Major Interactions (Avoid)

• Carbamazepine: may decrease levetiracetam plasma concentrations, reducing efficacy.
• Phenobarbital: can lower levetiracetam levels, potentially compromising seizure control.
• Other antiepileptics that induce hepatic enzymes: may reduce levetiracetam exposure.

Moderate Interactions (Monitor Closely)

• Alcohol: may enhance central nervous system depression.
• Opioids: increased risk of sedation and respiratory depression.
• Selective serotonin reuptake inhibitors (SSRIs): monitor for behavioral changes or increased irritability.